سعر بيتميجا 25 مجم 30 قرص ممتد المفعول 2022

Betmiga 25 mg prolonged-release tablets (mirabegron), pack of 30; Astellas marketed in Egypt via Multipharma.

• Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in adult overactive bladder (OAB) syndromePopulation: AdultsUK eMC / MHRA SmPC

• Most common in adults on 50 mg: tachycardia and urinary tract infections; serious reactions included atrial fibrillation (0.2%).International label, same formulation · UK eMC / MHRA SmPC

• Hypersensitivity to the active substance or excipients; severe uncontrolled hypertension (SBP ≥180 mmHg and/or DBP ≥110 mmHg).International label, same formulation · UK eMC / MHRA SmPC

• Mirabegron can increase blood pressure — measure at baseline and periodically. Caution in bladder outlet obstruction and with antimuscarinics for OAB (urinary retention reported). Not recommended in ESRD or severe hepatic impairment.International label, same formulation · UK eMC / MHRA SmPC

• CYP2D6 substrates (e.g. metoprolol, desipramine, thioridazine, flecainide, TCAs)ModerateMirabegron is a moderate CYP2D6 inhibitor; caution with narrow-therapeutic-index CYP2D6 substrates.UK eMC / MHRA SmPC
• DigoxinModerateMirabegron increases digoxin exposure; start digoxin at lowest dose and monitor serum levels.UK eMC / MHRA SmPC

• Not recommended during pregnancy; limited human data; animal studies showed reproductive toxicity.International label, same formulation · UK eMC / MHRA SmPC
• Should not be used during breast-feeding; predicted present in human milk based on rodent data.International label, same formulation · UK eMC / MHRA SmPC

• Mirabegron: Beta-3 adrenergic receptor agonist relaxing the detrusor smooth muscle during bladder filling, increasing bladder capacity.